The STAT3/JAK2 Signaling Pathway in Renal Fibrosis: Mechanistic Insights and Advances in Targeted Intervention.
文献摘要
Renal fibrosis remains a major therapeutic challenge in chronic kidney disease. Evidence for therapies targeting signal transducer and activator of transcription 3 (STAT3) is predominantly preclinical, although Janus kinase (JAK) inhibitors have been evaluated in diabetic kidney disease. This review compares STAT3 signaling across acute kidney injury progressing to chronic disease, diabetes, hypertension, and hyperuricemic kidney injury. Cytokine receptors, growth-factor receptors, metabolic stress, and interorgan signals influence STAT3 activity in tubular, stromal, and immune cells. Their effects depend on cellular context, activation dynamics, and interactions with other fibrotic pathways. We distinguish pathway-associated changes from functional validation and direct target engagement when assessing synthetic inhibitors, cell-based therapies, and natural or traditional-medicine-derived interventions. Clinical albuminuria findings are considered separately from evidence of fibrosis regression. Priorities include cell-resolved pharmacodynamic markers, intervention windows defined by repair state, and evaluation of targeted delivery.